Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
An Alternative Dose Interval Study in Participants With Hidradenitis Suppurativa Receiving Brodalumab
NCT04249713 · Rockefeller University · EARLY_PHASE1 · withdrawn · last registry update 2020-09-04 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Biomarker Samples Not Collected” | – | Registry record, Rockefeller University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL17RA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-08-20Results posted on the registry: Bausch Health Americas, Inc., 210 mg brodalumab + 140 mg brodalumab (NCT02024646)
- 2020-03-12Phase 3 first posted: LEO Pharma, Brodalumab + Ustekinumab (NCT04305327)
- 2020-02-10Results posted on the registry: LEO Pharma, Brodalumab + Fumaric acid esters (NCT03331835)
- 2020-01-06Results posted on the registry: Bausch Health Americas, Inc., 210 mg brodalumab + 140 mg brodalumab (NCT01708603)
- 2020-01-06Also stopped (terminated): Bausch Health Americas, Inc., 210 mg brodalumab + 140 mg brodalumab (NCT01708603)
- 2020-01-03Results posted on the registry: Bausch Health Americas, Inc., 210 mg brodalumab + 140 mg brodalumab (NCT01708590)
- 2020-01-03Also stopped (terminated): Bausch Health Americas, Inc., 210 mg brodalumab + 140 mg brodalumab (NCT01708590)
- 2020-01-03Results posted on the registry: Bausch Health Americas, Inc., 210 mg brodalumab + 140 mg brodalumab (NCT01708629)
- 2020-01-03Also stopped (terminated): Bausch Health Americas, Inc., 210 mg brodalumab + 140 mg brodalumab (NCT01708629)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision